PACS goes into wild blue yonder

Article

Agfa has received approval from the U.S. Air Force to operate its PACS technology. The company's Impax product line received a certificate of "networthiness" from the USAF by meeting guidelines defined by the Defense Information Systems Agency in

Agfa has received approval from the U.S. Air Force to operate its PACS technology. The company's Impax product line received a certificate of "networthiness" from the USAF by meeting guidelines defined by the Defense Information Systems Agency in accordance with Department of Defense regulations for IT security. Clearing those hurdles, specifically, were the Impax 4.5, the company's latest PACS; Impax Web1000, which provides secure remote access to enterprise-wide clinical images; and Agfa Mil-PACS RIS Gateway, which allows RIS and PACS technologies to communicate. The company has implemented more than $100 million in PACS and teleradiology systems at more than 75 DOD Medical Treatment Facilities worldwide, including 28 U.S. Navy warships and two U.S. Navy hospital ships.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.